Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab for airway hyperresponsiveness in severe asthma
ISRCTN70810039Phase 3Completed
- Sponsor
- University of Dundee
- Start
- Apr 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, open-label, single-arm trial of dupilumab in severe asthma and asthma, sponsored by University of Dundee. Primary endpoint: Airway hyperresponsiveness by mannitol PD10. Started Apr 2022; status: completed.
02
Drugs
03
Conditions
severe asthmaasthma
Beyond the preview
Go deeper on ISRCTN70810039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN70810039.